Target intelligence / Profile preview

Ribosomal protein L21 pseudogene 34 (RPL21P34)

Target: RPL21P34
Molecular classification: Other (pseudogene)

Overview

Ribosomal protein L21 pseudogene 34 (RPL21P34) is one of several processed genomic copies (pseudogenes) related to the RPL21 gene, which encodes a structural component of the large 60S ribosomal subunit for protein synthesis. These pseudogenes are common for ribosomal protein genes; however, RPL21P34 is not itself translated into a functional protein and lacks known biological roles, therapeutic relevance, or molecular interactions in current biomedical research. It may be annotated in genetic analyses or genomic databases, but is not considered a drug target or involved in human pathophysiology[1][5][6].

Other names: RPL21_6_274RPL21P34

Beyond the preview

Go deeper on Ribosomal protein L21 pseudogene 34 (RPL21P34).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ribosomal protein L21 pseudogene 34 (RPL21P34).

Explore the full profile